CA2594781A1 - Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases - Google Patents
Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases Download PDFInfo
- Publication number
- CA2594781A1 CA2594781A1 CA002594781A CA2594781A CA2594781A1 CA 2594781 A1 CA2594781 A1 CA 2594781A1 CA 002594781 A CA002594781 A CA 002594781A CA 2594781 A CA2594781 A CA 2594781A CA 2594781 A1 CA2594781 A1 CA 2594781A1
- Authority
- CA
- Canada
- Prior art keywords
- dha
- fatty acid
- epa
- acid composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 193
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 192
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 192
- 239000000194 fatty acid Substances 0.000 title claims abstract description 192
- 239000000203 mixture Substances 0.000 title claims abstract description 174
- 201000010099 disease Diseases 0.000 title claims abstract description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 64
- 206010002022 amyloidosis Diseases 0.000 title claims abstract description 59
- 206010002023 Amyloidoses Diseases 0.000 title claims abstract description 58
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 229940127554 medical product Drugs 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 49
- 230000002265 prevention Effects 0.000 claims abstract description 47
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 46
- 229940126601 medicinal product Drugs 0.000 claims abstract description 17
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims abstract description 14
- 206010021263 IgA nephropathy Diseases 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 241001465754 Metazoa Species 0.000 claims description 52
- 235000019198 oils Nutrition 0.000 claims description 32
- 208000024827 Alzheimer disease Diseases 0.000 claims description 25
- 235000015872 dietary supplement Nutrition 0.000 claims description 18
- 230000000813 microbial effect Effects 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 235000013311 vegetables Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000021323 fish oil Nutrition 0.000 claims description 10
- 125000005457 triglyceride group Chemical group 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 150000003839 salts Chemical group 0.000 claims description 8
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 208000037976 chronic inflammation Diseases 0.000 claims description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 5
- 239000001828 Gelatine Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 256
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 133
- 229940090949 docosahexaenoic acid Drugs 0.000 description 132
- 239000003921 oil Substances 0.000 description 24
- 230000003941 amyloidogenesis Effects 0.000 description 18
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 18
- 230000003449 preventive effect Effects 0.000 description 18
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 235000008390 olive oil Nutrition 0.000 description 15
- 239000004006 olive oil Substances 0.000 description 15
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 13
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 13
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 13
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 13
- 239000005642 Oleic acid Substances 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 13
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 13
- 235000021313 oleic acid Nutrition 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000021342 arachidonic acid Nutrition 0.000 description 9
- 229940114079 arachidonic acid Drugs 0.000 description 9
- 230000008021 deposition Effects 0.000 description 9
- 229910001961 silver nitrate Inorganic materials 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 208000037259 Amyloid Plaque Diseases 0.000 description 7
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 7
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006014 omega-3 oil Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000001049 Amyloid Human genes 0.000 description 5
- 108010094108 Amyloid Proteins 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 3
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 3
- 208000023769 AA amyloidosis Diseases 0.000 description 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 3
- 101100286193 Homo sapiens IAPP gene Proteins 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 206010039811 Secondary amyloidosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229940105305 carbon monoxide Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64560405P | 2005-01-24 | 2005-01-24 | |
| SE0500174-8 | 2005-01-24 | ||
| SE0500174 | 2005-01-24 | ||
| US60/645,604 | 2005-01-24 | ||
| PCT/IB2006/000106 WO2006077495A1 (en) | 2005-01-24 | 2006-01-24 | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2594781A1 true CA2594781A1 (en) | 2006-07-27 |
Family
ID=36692011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002594781A Abandoned CA2594781A1 (en) | 2005-01-24 | 2006-01-24 | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090054523A1 (enExample) |
| EP (1) | EP1845999A4 (enExample) |
| JP (1) | JP5503846B2 (enExample) |
| KR (1) | KR101253696B1 (enExample) |
| CA (1) | CA2594781A1 (enExample) |
| NO (1) | NO343234B1 (enExample) |
| WO (1) | WO2006077495A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| EP3263101A1 (en) | 2005-12-21 | 2018-01-03 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| KR100879816B1 (ko) | 2007-05-31 | 2009-01-22 | 학교법인 일송학원 | 꽁치류의 가수분해물을 포함하는 허혈성 뇌혈관질환 예방또는 개선용 조성물 |
| PT2374452T (pt) * | 2008-12-05 | 2019-10-31 | Ajinomoto Kk | Composição de nutrientes |
| CN108324706A (zh) * | 2009-02-02 | 2018-07-27 | 帝斯曼知识产权资产有限公司 | 改善认知功能和降低心率的方法 |
| US9532963B2 (en) * | 2009-03-09 | 2017-01-03 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| US20100239660A1 (en) * | 2009-03-19 | 2010-09-23 | Doughman Scott D | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions |
| US8124574B2 (en) | 2009-10-12 | 2012-02-28 | Conopco, Inc. | Mild, foaming liquid cleansers comprising low levels of fatty isethionate product and low total fatty acid and/or fatty acid soap content |
| US8105994B2 (en) | 2010-03-31 | 2012-01-31 | Conopco, Inc. | Personal wash cleanser comprising defined alkanoyl compounds, defined fatty acyl isethionate surfactant product and skin or hair benefit agent delivered in flocs upon dilution |
| CN107050457A (zh) | 2012-01-06 | 2017-08-18 | 翁特拉制药公司 | 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物 |
| EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
| KR20220010415A (ko) * | 2020-07-17 | 2022-01-25 | 대봉엘에스 주식회사 | 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0707487B1 (en) * | 1993-06-09 | 2004-04-14 | Martek Biosciences Corporation | Methods and pharmaceutical compositions useful for treating neurological disorders |
| JPH07268385A (ja) * | 1994-03-31 | 1995-10-17 | Snow Brand Milk Prod Co Ltd | 魚臭が低減されたカツオおよび／またはマグロ油 |
| JPH09511533A (ja) * | 1994-09-19 | 1997-11-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | 顆粒状漂白組成物 |
| JPH08143454A (ja) * | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
| EP0831805A1 (en) * | 1995-06-07 | 1998-04-01 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US6395778B1 (en) * | 2000-01-11 | 2002-05-28 | Omegatech, Inc. | Process for making an enriched mixture of polyunsaturated fatty acid esters |
| US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| CN1380058A (zh) * | 2001-04-10 | 2002-11-20 | 上海体育运动技术学院 | 用于促进人体自身epa、dha合成的药物 |
| US20030077342A1 (en) * | 2001-10-09 | 2003-04-24 | Maf Group, Llc | Anti-inflammatory complex containing eicosapentaenoic acid |
| AU2002352726A1 (en) * | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
-
2006
- 2006-01-24 WO PCT/IB2006/000106 patent/WO2006077495A1/en not_active Ceased
- 2006-01-24 CA CA002594781A patent/CA2594781A1/en not_active Abandoned
- 2006-01-24 JP JP2007551765A patent/JP5503846B2/ja not_active Expired - Fee Related
- 2006-01-24 US US11/795,800 patent/US20090054523A1/en not_active Abandoned
- 2006-01-24 EP EP06710253A patent/EP1845999A4/en not_active Withdrawn
-
2007
- 2007-08-22 KR KR20077019198A patent/KR101253696B1/ko not_active Expired - Fee Related
- 2007-08-23 NO NO20074318A patent/NO343234B1/no not_active IP Right Cessation
-
2012
- 2012-06-21 US US13/529,592 patent/US20120277317A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101253696B1 (ko) | 2013-04-12 |
| EP1845999A1 (en) | 2007-10-24 |
| NO20074318L (no) | 2007-10-24 |
| WO2006077495A1 (en) | 2006-07-27 |
| KR20070104917A (ko) | 2007-10-29 |
| EP1845999A4 (en) | 2010-09-22 |
| JP2008528475A (ja) | 2008-07-31 |
| US20090054523A1 (en) | 2009-02-26 |
| JP5503846B2 (ja) | 2014-05-28 |
| NO343234B1 (no) | 2018-12-17 |
| US20120277317A1 (en) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8609726B2 (en) | Fatty acid composition for treatment of Alzheimer's disease and cognitive dysfunction | |
| US20120277317A1 (en) | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases | |
| CN102245176B (zh) | 用作药物的脂肪酸 | |
| CN106349058B (zh) | 多不饱和脂肪酸的衍生物作为药物的用途 | |
| US20140107206A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| CZ20012947A3 (cs) | Pouľití esenciálních mastných kyselin pro prevenci kardiovaskulárních příhod | |
| AU2015229240B9 (en) | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances | |
| WO2007043870A1 (en) | Leucine rich composition | |
| US8461141B2 (en) | Preventive or therapeutic drug for Alzheimer-type dementia | |
| WO2014158256A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| JP2013216679A (ja) | 非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬 | |
| CN101001620B (zh) | α-酮基戊二酸和相关化合物用于降低血脂的用途 | |
| US20040235948A1 (en) | Treatment of diabetic patients with omega-3-fatty acids | |
| JPH04273817A (ja) | 低密度リポ蛋白受容体活性化剤 | |
| WO2023037375A1 (en) | A self-emulsifying drug delivery system (sedds) of punicic acid combined with neuroprotective natural products to delay onset, prevent, or reverse neurodegenerative disease | |
| US12576059B2 (en) | Methods and compositions for treatment of inflammatory disease | |
| AU2005244483B2 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| US20090016991A1 (en) | Rxr Antagonist Treatment Against Multiple Sclerosis | |
| CA3234879A1 (en) | Medium chain dicarboxylic acids for the treatment and prevention of diseases and conditions | |
| CN119730845A (zh) | 用于改善视网膜/认知功能和动脉粥样硬化的极长链多不饱和脂肪酸（vlcpufa） | |
| HK40009140A (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
| JPH05117147A (ja) | 痴呆疾患の治療または予防の為の組成物と、それを処方物にした抗痴呆薬 | |
| JPH07188006A (ja) | 悪液質用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |